Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma

Abstract

Our pathological study of a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma suggested that immune checkpoint inhibitor may be an effective therapy. The histological type is an important factor in determining treatment choices.

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma

“…In particular, the 2019 World Health Organization classification mentions lymphocyte-rich HCC [88]. This rare variant (<1%) is characterised by an abundant lymphocyte infiltration and a high PD-L1 expression rate on surrounding inflammatory cells [87], suggesting a possible good response to ICIs [89]. Surely, more data about histologic variants might help to achieve a better understanding of response and resistance to ICIs.…”